Exploring Potential Drug Targets for SLE Through Mendelian Randomization and Network Pharmacology

Overview

Journal PLoS One

Date 2025 Jan 17

PMID 39823480

Authors

Yanan Xu

Zelin Wang

Tiewen Jia

Shufen Liang

Affiliations

Soon will be listed here.

Abstract

Background: Systemic lupus erythematosus (SLE) is a complex and incurable autoimmune disease, so several drug remission for SLE symptoms have been developed and used at present. However, treatment varies by patient and disease activity, and existing medications for SLE were far from satisfactory. Novel drug targets to be found for SLE therapy are still needed.

Methods: Mendelian randomization (MR), an observational study way, was performed to explore potential drug targets for SLE using protein quantitative trait loci (pQTL) from recently published genome-wide association studies (GWAS) of cerebrospinal fluid (CSF) and plasma proteins, which obtained genetic instruments for 154 CSF proteins of 971 participants, and 734 plasma proteins of 23591 participants. Bidirectional Mendelian randomization analysis, colocalization analysis, and phenotype scanning were performed to find key proteins for SLE. In addition, external data verification was implemented to further consolidate the Mendelian randomization findings. Candidate proteins as targets to find drugs and discuss the druggability. Finally, Network pharmacology and molecular docking methods were used to verify the effects of Voclosporin and Cyclosporine on SLE targets. Protein-protein interaction (PPI) and core target analysis of candidate drugs and SLE overlapping targets were performed to identify potential hub targets and interactions. The affinity between drug targets and SLE targets was confirmed by molecular docking.

Results: In the preliminary analysis, we identified four key proteins as possible drug targets in CSF and plasma proteins, included ICAM-1(P = 4.62E-05, OR = 0.90(0.86, 0.95)), sICAM-1(P = 4.62E-05, OR = 0.49(0.35, 0.69)), FCG2B (P = 7.63E-11, OR = 0.57(0.48, 0.67)), PPP3CA; PPP3R1 (P = 5.47E-07, OR = 0.66(0.57, 0.78)). Among them, ICAM1 was detected in both CSF and plasma proteins. By excluding reverse causality, confounding factors, and linkage disequilibrium (LD), we identified PPP3CA; PPP3R1 as novel drug targets for SLE, including Voclosporin and Cyclosporine. Finally, the Drugbank database shows that novel drugs contain 33 targets for treating SLE. PPI suggested that SIRT1, ACE, PTGS2, and BACE1 were pivotal targets for SLE treatment. In addition, the molecular docking showed that the bioactive molecules of Voclosporin and Cyclosporine had a good affinity with the target of SLE.

Conclusions: Our integrative analysis suggested that levels of circulating PPP3CA; PPP3R1 had causal effects on SLE risk and served as potential treatment targets. Moreover, this study provides new evidence for Voclosporin as an SLE treatment through Mendelian randomization and Network pharmacology, and warrants further clinical investigation.

References

Rees F, Doherty M, Grainge M, Lanyon P, Zhang W . The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017; 56(11):1945-1961. DOI: 10.1093/rheumatology/kex260. View

Zheng J, Haberland V, Baird D, Walker V, Haycock P, Hurle M . Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020; 52(10):1122-1131. PMC: 7610464. DOI: 10.1038/s41588-020-0682-6. View

Burgess S, Scott R, Timpson N, Davey Smith G, Thompson S . Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015; 30(7):543-52. PMC: 4516908. DOI: 10.1007/s10654-015-0011-z. View

Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F . Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. 2021; 50(D1):D1398-D1407. PMC: 8728281. DOI: 10.1093/nar/gkab953. View

Suhre K, Arnold M, Mukund Bhagwat A, Cotton R, Engelke R, Raffler J . Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017; 8:14357. PMC: 5333359. DOI: 10.1038/ncomms14357. View

Burgess S, Thompson S . Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011; 40(3):755-64. DOI: 10.1093/ije/dyr036. View

Yang C, Farias F, Ibanez L, Suhy A, Sadler B, Fernandez M . Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat Neurosci. 2021; 24(9):1302-1312. PMC: 8521603. DOI: 10.1038/s41593-021-00886-6. View

Zhou Z, Bai J, Zhong S, Zhang R, Kang K, Zhang X . Integrative genomic analysis of PPP3R1 in Alzheimer's disease: a potential biomarker for predictive, preventive, and personalized medical approach. EPMA J. 2021; 12(4):647-658. PMC: 8648944. DOI: 10.1007/s13167-021-00261-2. View

Nelson M, Tipney H, Painter J, Shen J, Nicoletti P, Shen Y . The support of human genetic evidence for approved drug indications. Nat Genet. 2015; 47(8):856-60. DOI: 10.1038/ng.3314. View

10.

Panneerselvam S, Wang J, Zhu W, Dai H, Pappas J, Rabin R . PPP3CA truncating variants clustered in the regulatory domain cause early-onset refractory epilepsy. Clin Genet. 2021; 100(2):227-233. PMC: 11698261. DOI: 10.1111/cge.13979. View

11.

Wang Y, Zhang Y, Lin Z, Zhang H, Wang T, Cao Y . Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups. Nat Commun. 2021; 12(1):772. PMC: 7858632. DOI: 10.1038/s41467-021-21049-y. View

12.

Hansson O . Biomarkers for neurodegenerative diseases. Nat Med. 2021; 27(6):954-963. DOI: 10.1038/s41591-021-01382-x. View

13.

Creamer T . Calcineurin. Cell Commun Signal. 2020; 18(1):137. PMC: 7456046. DOI: 10.1186/s12964-020-00636-4. View

14.

Bui T, Wiesolek H, Sumagin R . ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020; 108(3):787-799. PMC: 7977775. DOI: 10.1002/JLB.2MR0220-549R. View

15.

Davies N, Holmes M, Davey Smith G . Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMC: 6041728. DOI: 10.1136/bmj.k601. View

16.

Peterson D, Munger C, Crowley J, Corcoran C, Cruchaga C, Goate A . Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study. Alzheimers Dement. 2013; 10(3):366-71. PMC: 3809344. DOI: 10.1016/j.jalz.2013.02.010. View

17.

Swulius M, Waxham M . Ca(2+)/calmodulin-dependent protein kinases. Cell Mol Life Sci. 2008; 65(17):2637-57. PMC: 3617042. DOI: 10.1007/s00018-008-8086-2. View

18.

Montgomery S, Dermitzakis E . From expression QTLs to personalized transcriptomics. Nat Rev Genet. 2011; 12(4):277-82. DOI: 10.1038/nrg2969. View

19.

Kyogoku C, Dijstelbloem H, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A . Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 2002; 46(5):1242-54. DOI: 10.1002/art.10257. View

20.

Qiu Y, Zhou X, Liu Y, Tan S, Li Y . The Role of Sirtuin-1 in Immune Response and Systemic Lupus Erythematosus. Front Immunol. 2021; 12:632383. PMC: 8110204. DOI: 10.3389/fimmu.2021.632383. View